This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-106b-5p | AKT3 | 2.81 | 0 | -3.33 | 1.0E-5 | miRNATAP | -0.41 | 1.0E-5 | NA | |
2 | hsa-miR-142-3p | AKT3 | 4.35 | 0 | -3.33 | 1.0E-5 | miRanda | -0.16 | 0.00934 | NA | |
3 | hsa-miR-15a-5p | AKT3 | 2.05 | 0 | -3.33 | 1.0E-5 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.37 | 0.00021 | NA | |
4 | hsa-miR-15b-5p | AKT3 | 3.32 | 0 | -3.33 | 1.0E-5 | miRNATAP | -0.25 | 0.00571 | NA | |
5 | hsa-miR-16-5p | AKT3 | 2.94 | 0 | -3.33 | 1.0E-5 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.31 | 0.00086 | NA | |
6 | hsa-miR-29b-3p | AKT3 | 0.67 | 0.23406 | -3.33 | 1.0E-5 | miRNATAP | -0.28 | 0.00031 | 26512921 | MicroRNA 29B mir 29b regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3 |
7 | hsa-miR-3065-5p | AKT3 | 2.14 | 0.06094 | -3.33 | 1.0E-5 | mirMAP | -0.22 | 0 | NA | |
8 | hsa-miR-362-3p | AKT3 | 0.68 | 0.22615 | -3.33 | 1.0E-5 | miRanda | -0.25 | 0.00124 | NA | |
9 | hsa-miR-501-3p | AKT3 | 1.72 | 0.00759 | -3.33 | 1.0E-5 | miRNATAP | -0.18 | 0.00733 | NA | |
10 | hsa-miR-93-5p | AKT3 | 2.66 | 0 | -3.33 | 1.0E-5 | miRNATAP | -0.33 | 0.00021 | NA | |
11 | hsa-miR-582-5p | CHP2 | 0.69 | 0.44776 | 1.48 | 0.50956 | miRNATAP | -0.42 | 0.00313 | NA | |
12 | hsa-miR-130a-5p | KDR | 1.58 | 0.02435 | -3.79 | 0 | mirMAP | -0.17 | 0.00459 | NA | |
13 | hsa-miR-149-5p | KDR | 1.19 | 0.19744 | -3.79 | 0 | miRNATAP | -0.17 | 0.00011 | NA | |
14 | hsa-miR-15a-5p | KDR | 2.05 | 0 | -3.79 | 0 | miRNATAP | -0.34 | 0.00024 | NA | |
15 | hsa-miR-15b-5p | KDR | 3.32 | 0 | -3.79 | 0 | miRNATAP | -0.44 | 0 | NA | |
16 | hsa-miR-16-5p | KDR | 2.94 | 0 | -3.79 | 0 | miRTarBase; miRNATAP | -0.49 | 0 | 26934556 | The expression levels of two target genes Myb and VEGFR2 were affected significantly by miR-16 while glucose administration inhibited miR-16 expression and enhanced tumor cell proliferation and migration; Hyperglycemia can impact the clinical outcomes of CRC patients likely by inhibiting miR-16 expression and the expression of its downstream genes Myb and VEGFR2 |
17 | hsa-miR-19b-1-5p | KDR | 1.51 | 0.00147 | -3.79 | 0 | miRNAWalker2 validate | -0.37 | 1.0E-5 | NA | |
18 | hsa-miR-200b-3p | KDR | 5.56 | 0 | -3.79 | 0 | miRNAWalker2 validate; miRTarBase; TargetScan | -0.29 | 0 | NA | |
19 | hsa-miR-200c-3p | KDR | 6.47 | 0 | -3.79 | 0 | miRNATAP | -0.38 | 0 | 24205206 | MiR 200c increases the radiosensitivity of non small cell lung cancer cell line A549 by targeting VEGF VEGFR2 pathway; MiR-200c at the nexus of epithelial-mesenchymal transition EMT is predicted to target VEGFR2; The purpose of this study is to test the hypothesis that regulation of VEGFR2 pathway by miR-200c could modulate the radiosensitivity of cancer cells; Bioinformatic analysis luciferase reporter assays and biochemical assays were carried out to validate VEGFR2 as a direct target of miR-200c; We identified VEGFR2 as a novel target of miR-200c |
20 | hsa-miR-3065-3p | KDR | 1.89 | 0.03082 | -3.79 | 0 | miRNATAP | -0.15 | 0.00082 | NA | |
21 | hsa-miR-429 | KDR | 6.4 | 0 | -3.79 | 0 | PITA; miRanda; miRNATAP | -0.25 | 0 | NA | |
22 | hsa-miR-590-3p | KDR | 2.35 | 0 | -3.79 | 0 | miRanda | -0.29 | 0.00023 | NA | |
23 | hsa-miR-590-5p | KDR | 1.51 | 0.00239 | -3.79 | 0 | miRanda | -0.23 | 0.00499 | NA | |
24 | hsa-miR-590-3p | KRAS | 2.35 | 0 | 0.4 | 0.26791 | PITA; miRanda; mirMAP | -0.1 | 0.00867 | NA | |
25 | hsa-miR-101-3p | MAP2K1 | -1.12 | 0.02009 | 0.52 | 0.11376 | miRNAWalker2 validate | -0.21 | 0 | NA | |
26 | hsa-miR-140-3p | MAP2K1 | -1.98 | 0 | 0.52 | 0.11376 | PITA | -0.13 | 0.00693 | NA | |
27 | hsa-miR-497-5p | MAP2K1 | -1.44 | 0.02251 | 0.52 | 0.11376 | miRNAWalker2 validate | -0.16 | 0 | NA | |
28 | hsa-miR-148b-3p | MAPK1 | 1.76 | 0 | 0.01 | 0.9644 | mirMAP | -0.14 | 0.00442 | NA | |
29 | hsa-miR-29b-2-5p | MAPK1 | -0.6 | 0.18954 | 0.01 | 0.9644 | mirMAP | -0.15 | 2.0E-5 | NA | |
30 | hsa-miR-29c-3p | MAPK1 | -0.41 | 0.52934 | 0.01 | 0.9644 | mirMAP | -0.12 | 0 | NA | |
31 | hsa-miR-30b-5p | MAPK1 | 0.02 | 0.95322 | 0.01 | 0.9644 | mirMAP | -0.11 | 0.00754 | NA | |
32 | hsa-miR-30e-5p | MAPK1 | 0.78 | 0.03467 | 0.01 | 0.9644 | mirMAP | -0.12 | 0.00886 | NA | |
33 | hsa-miR-3913-5p | MAPK1 | 0.15 | 0.73484 | 0.01 | 0.9644 | mirMAP | -0.11 | 0.0044 | NA | |
34 | hsa-miR-324-3p | MAPKAPK2 | 1.51 | 0.00384 | 0.04 | 0.888 | MirTarget | -0.12 | 0.00014 | NA | |
35 | hsa-miR-148b-5p | NFAT5 | 2.81 | 0 | -0.87 | 0.01428 | MirTarget | -0.1 | 0.0096 | NA | |
36 | hsa-miR-15b-3p | NFAT5 | 3.58 | 0 | -0.87 | 0.01428 | mirMAP | -0.13 | 0.00043 | NA | |
37 | hsa-miR-16-1-3p | NFAT5 | 2.83 | 0 | -0.87 | 0.01428 | mirMAP | -0.13 | 0.00125 | NA | |
38 | hsa-miR-21-3p | NFAT5 | 3.5 | 0 | -0.87 | 0.01428 | MirTarget | -0.12 | 0.00062 | NA | |
39 | hsa-miR-25-3p | NFAT5 | 1.13 | 0.00311 | -0.87 | 0.01428 | miRNATAP | -0.22 | 3.0E-5 | NA | |
40 | hsa-miR-27b-5p | NFAT5 | 0.21 | 0.71562 | -0.87 | 0.01428 | miRNATAP | -0.11 | 0.00144 | NA | |
41 | hsa-miR-361-3p | NFAT5 | 0.81 | 0.04185 | -0.87 | 0.01428 | MirTarget; PITA; miRNATAP | -0.14 | 0.00508 | NA | |
42 | hsa-miR-3613-5p | NFAT5 | 4.05 | 0 | -0.87 | 0.01428 | miRNATAP | -0.1 | 0.00389 | NA | |
43 | hsa-miR-374a-3p | NFAT5 | 0.47 | 0.30527 | -0.87 | 0.01428 | mirMAP | -0.13 | 0.00396 | NA | |
44 | hsa-miR-16-2-3p | NFATC2 | 3.8 | 0 | -0.29 | 0.824 | mirMAP | -0.51 | 0.0002 | NA | |
45 | hsa-miR-182-5p | NFATC2 | 5.87 | 0 | -0.29 | 0.824 | mirMAP | -0.32 | 0.00065 | NA | |
46 | hsa-miR-19b-3p | NFATC2 | 1.68 | 0.00086 | -0.29 | 0.824 | mirMAP | -0.4 | 0.00522 | NA | |
47 | hsa-miR-221-3p | NFATC2 | 0.94 | 0.17475 | -0.29 | 0.824 | MirTarget | -0.38 | 0.00031 | NA | |
48 | hsa-miR-222-3p | NFATC2 | 1.55 | 0.0223 | -0.29 | 0.824 | MirTarget | -0.4 | 0.0002 | NA | |
49 | hsa-miR-2355-5p | NFATC2 | 0.42 | 0.50215 | -0.29 | 0.824 | MirTarget | -0.4 | 0.00064 | NA | |
50 | hsa-miR-24-3p | NFATC2 | 1.56 | 0.00052 | -0.29 | 0.824 | MirTarget | -0.47 | 0.00386 | NA | |
51 | hsa-miR-26b-3p | NFATC2 | 0.99 | 0.03514 | -0.29 | 0.824 | MirTarget | -0.42 | 0.00685 | NA | |
52 | hsa-miR-27b-5p | NFATC2 | 0.21 | 0.71562 | -0.29 | 0.824 | mirMAP | -0.56 | 1.0E-5 | NA | |
53 | hsa-miR-30b-5p | NFATC2 | 0.02 | 0.95322 | -0.29 | 0.824 | MirTarget; mirMAP | -0.7 | 0.0001 | NA | |
54 | hsa-miR-335-3p | NFATC2 | 1.2 | 0.09389 | -0.29 | 0.824 | mirMAP | -0.28 | 0.00699 | NA | |
55 | hsa-miR-33a-3p | NFATC2 | 2.06 | 0.00156 | -0.29 | 0.824 | mirMAP | -0.49 | 1.0E-5 | NA | |
56 | hsa-miR-3607-3p | NFATC2 | 1.38 | 0.02401 | -0.29 | 0.824 | MirTarget; mirMAP | -0.39 | 0.00099 | NA | |
57 | hsa-miR-590-3p | NFATC2 | 2.35 | 0 | -0.29 | 0.824 | mirMAP | -0.38 | 0.00751 | NA | |
58 | hsa-miR-9-5p | NFATC2 | 1.8 | 0.14527 | -0.29 | 0.824 | MirTarget | -0.18 | 0.00223 | NA | |
59 | hsa-miR-29a-3p | NFATC3 | -0.64 | 0.25192 | 0.48 | 0.1068 | MirTarget; miRNATAP | -0.14 | 0 | NA | |
60 | hsa-miR-30a-5p | NFATC3 | -0.77 | 0.32049 | 0.48 | 0.1068 | MirTarget; miRNATAP | -0.11 | 0 | NA | |
61 | hsa-miR-505-3p | NFATC3 | 0.59 | 0.22694 | 0.48 | 0.1068 | mirMAP | -0.1 | 0.00323 | NA | |
62 | hsa-miR-15b-3p | NFATC4 | 3.58 | 0 | -3.51 | 3.0E-5 | mirMAP | -0.33 | 0.00011 | NA | |
63 | hsa-miR-193a-3p | NFATC4 | 0.65 | 0.20713 | -3.51 | 3.0E-5 | miRanda | -0.33 | 0.00048 | NA | |
64 | hsa-miR-2355-5p | NFATC4 | 0.42 | 0.50215 | -3.51 | 3.0E-5 | MirTarget | -0.22 | 0.0045 | NA | |
65 | hsa-miR-29b-3p | NFATC4 | 0.67 | 0.23406 | -3.51 | 3.0E-5 | miRNATAP | -0.27 | 0.00195 | NA | |
66 | hsa-miR-484 | NFATC4 | 1.79 | 0.00022 | -3.51 | 3.0E-5 | MirTarget; miRNATAP | -0.33 | 0.00085 | NA | |
67 | hsa-miR-629-3p | NFATC4 | 3.48 | 0 | -3.51 | 3.0E-5 | mirMAP | -0.45 | 0 | NA | |
68 | hsa-miR-429 | NOS3 | 6.4 | 0 | -3.31 | 0 | miRanda | -0.18 | 0.00014 | NA | |
69 | hsa-miR-26a-5p | NRAS | -0.35 | 0.36204 | 1.26 | 1.0E-5 | mirMAP; miRNATAP | -0.17 | 3.0E-5 | 26458859 | MiR 26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2; Our results suggest that miR-26a can improve the sensitivity of GC cells to cisplatin-based chemotherapies through targeting NRAS and E2F2 and provide the first evidence of the potential utility of miR-26a as a sensitizer in chemotherapy for GC |
70 | hsa-miR-28-5p | NRAS | -0.82 | 0.02212 | 1.26 | 1.0E-5 | MirTarget; PITA; miRanda; miRNATAP | -0.12 | 0.00589 | NA | |
71 | hsa-miR-29c-3p | NRAS | -0.41 | 0.52934 | 1.26 | 1.0E-5 | miRNATAP | -0.11 | 1.0E-5 | NA | |
72 | hsa-miR-148b-3p | PIK3CA | 1.76 | 0 | 0.51 | 0.24893 | miRNAWalker2 validate | -0.24 | 0.00148 | NA | |
73 | hsa-miR-186-5p | PIK3CA | 0.45 | 0.18545 | 0.51 | 0.24893 | mirMAP | -0.28 | 0.00023 | NA | |
74 | hsa-miR-29b-1-5p | PIK3CA | 0.34 | 0.59809 | 0.51 | 0.24893 | mirMAP | -0.12 | 0.00234 | NA | |
75 | hsa-miR-320b | PIK3CA | 0.2 | 0.72722 | 0.51 | 0.24893 | miRanda | -0.12 | 0.00551 | NA | |
76 | hsa-miR-335-5p | PIK3CA | 0.17 | 0.8039 | 0.51 | 0.24893 | miRNAWalker2 validate | -0.12 | 0.00088 | NA | |
77 | hsa-miR-338-5p | PIK3CA | -0.11 | 0.89468 | 0.51 | 0.24893 | mirMAP | -0.11 | 0.00047 | NA | |
78 | hsa-miR-339-5p | PIK3CA | 1.23 | 0.03075 | 0.51 | 0.24893 | miRanda | -0.14 | 0.00178 | NA | |
79 | hsa-miR-501-5p | PIK3CA | 1.04 | 0.07772 | 0.51 | 0.24893 | mirMAP | -0.12 | 0.00474 | NA | |
80 | hsa-miR-130a-3p | PIK3CB | 0.18 | 0.75775 | 0.9 | 0.01258 | miRNATAP | -0.12 | 0.00106 | NA | |
81 | hsa-miR-19b-3p | PIK3CB | 1.68 | 0.00086 | 0.9 | 0.01258 | miRNATAP | -0.11 | 0.00639 | NA | |
82 | hsa-miR-1468-5p | PIK3CD | -1.63 | 0.00779 | 0.06 | 0.92656 | MirTarget | -0.15 | 0.0056 | NA | |
83 | hsa-miR-199a-5p | PIK3CD | -1.25 | 0.07478 | 0.06 | 0.92656 | MirTarget; PITA; miRanda; miRNATAP | -0.16 | 0.00086 | NA | |
84 | hsa-miR-30d-5p | PIK3CD | 0.3 | 0.38019 | 0.06 | 0.92656 | MirTarget; miRNATAP | -0.27 | 0.00723 | NA | |
85 | hsa-miR-3913-5p | PIK3CD | 0.15 | 0.73484 | 0.06 | 0.92656 | mirMAP | -0.26 | 0.00117 | NA | |
86 | hsa-miR-335-3p | PIK3CG | 1.2 | 0.09389 | -0.16 | 0.84867 | mirMAP | -0.29 | 1.0E-5 | NA | |
87 | hsa-miR-16-2-3p | PIK3R1 | 3.8 | 0 | -1.85 | 0.01274 | MirTarget | -0.22 | 0.0055 | NA | |
88 | hsa-miR-16-5p | PIK3R1 | 2.94 | 0 | -1.85 | 0.01274 | MirTarget | -0.23 | 0.00941 | NA | |
89 | hsa-miR-17-5p | PIK3R1 | 2.33 | 2.0E-5 | -1.85 | 0.01274 | MirTarget; TargetScan; miRNATAP | -0.26 | 0.00056 | NA | |
90 | hsa-miR-200c-3p | PIK3R1 | 6.47 | 0 | -1.85 | 0.01274 | mirMAP | -0.21 | 0.00097 | NA | |
91 | hsa-miR-29b-3p | PIK3R1 | 0.67 | 0.23406 | -1.85 | 0.01274 | MirTarget; miRNATAP | -0.23 | 0.00248 | NA | |
92 | hsa-miR-3065-5p | PIK3R1 | 2.14 | 0.06094 | -1.85 | 0.01274 | MirTarget; mirMAP; miRNATAP | -0.14 | 0.003 | NA | |
93 | hsa-miR-320c | PIK3R1 | -0.11 | 0.854 | -1.85 | 0.01274 | miRNATAP | -0.24 | 0.00153 | NA | |
94 | hsa-miR-330-3p | PIK3R1 | 2.49 | 0.00013 | -1.85 | 0.01274 | MirTarget; PITA; miRNATAP | -0.22 | 0.00056 | NA | |
95 | hsa-miR-335-3p | PIK3R1 | 1.2 | 0.09389 | -1.85 | 0.01274 | mirMAP | -0.19 | 0.00155 | NA | |
96 | hsa-miR-338-5p | PIK3R1 | -0.11 | 0.89468 | -1.85 | 0.01274 | PITA | -0.15 | 0.00415 | NA | |
97 | hsa-miR-582-5p | PIK3R1 | 0.69 | 0.44776 | -1.85 | 0.01274 | mirMAP | -0.17 | 0.00029 | NA | |
98 | hsa-miR-584-5p | PIK3R1 | 1.18 | 0.20286 | -1.85 | 0.01274 | mirMAP | -0.26 | 0 | NA | |
99 | hsa-miR-590-5p | PIK3R1 | 1.51 | 0.00239 | -1.85 | 0.01274 | MirTarget; PITA; miRanda; miRNATAP | -0.3 | 0.00045 | NA | |
100 | hsa-miR-629-3p | PIK3R1 | 3.48 | 0 | -1.85 | 0.01274 | MirTarget | -0.21 | 0.00106 | NA | |
101 | hsa-miR-1271-5p | PIK3R3 | 0.21 | 0.74254 | -0.03 | 0.95933 | mirMAP | -0.15 | 0.003 | NA | |
102 | hsa-miR-18a-3p | PIK3R3 | 3.65 | 0 | -0.03 | 0.95933 | miRNAWalker2 validate | -0.17 | 9.0E-5 | NA | |
103 | hsa-miR-222-5p | PIK3R3 | 2.52 | 0.00142 | -0.03 | 0.95933 | mirMAP | -0.17 | 4.0E-5 | NA | |
104 | hsa-miR-29b-1-5p | PIK3R3 | 0.34 | 0.59809 | -0.03 | 0.95933 | mirMAP | -0.21 | 3.0E-5 | NA | |
105 | hsa-miR-330-3p | PIK3R3 | 2.49 | 0.00013 | -0.03 | 0.95933 | MirTarget | -0.19 | 0.00014 | NA | |
106 | hsa-miR-330-5p | PIK3R3 | 2.25 | 0.00028 | -0.03 | 0.95933 | miRanda | -0.16 | 0.00263 | NA | |
107 | hsa-miR-365a-3p | PIK3R3 | 0.26 | 0.65432 | -0.03 | 0.95933 | MirTarget | -0.33 | 0 | NA | |
108 | hsa-miR-511-5p | PIK3R3 | 1.1 | 0.17928 | -0.03 | 0.95933 | MirTarget | -0.18 | 1.0E-5 | 25608840 | MiR 511 inhibits growth and metastasis of human hepatocellular carcinoma cells by targeting PIK3R3; We further demonstrated that miR-511 suppressed HCC cell proliferation migration and invasion by repressing PIK3R3 expression |
109 | hsa-miR-590-5p | PIK3R3 | 1.51 | 0.00239 | -0.03 | 0.95933 | miRanda | -0.2 | 0.00312 | NA | |
110 | hsa-miR-125a-3p | PIK3R5 | -0.07 | 0.92074 | 0.76 | 0.28692 | miRanda | -0.14 | 0.00747 | NA | |
111 | hsa-miR-125a-5p | PIK3R5 | -1.32 | 0.00714 | 0.76 | 0.28692 | MirTarget; miRanda | -0.25 | 0.00223 | NA | |
112 | hsa-miR-182-5p | PIK3R5 | 5.87 | 0 | 0.76 | 0.28692 | MirTarget | -0.25 | 0 | NA | |
113 | hsa-miR-142-3p | PLA2G12A | 4.35 | 0 | -0.35 | 0.22836 | miRanda | -0.1 | 1.0E-5 | NA | |
114 | hsa-miR-142-5p | PLA2G12A | 3.96 | 0 | -0.35 | 0.22836 | mirMAP | -0.13 | 0 | NA | |
115 | hsa-miR-491-5p | PLA2G2A | 0.57 | 0.31331 | -3.35 | 0.08529 | miRanda | -0.56 | 0.00483 | NA | |
116 | hsa-miR-125a-5p | PLA2G2F | -1.32 | 0.00714 | 4.61 | 0.01694 | mirMAP | -1.06 | 0 | NA | |
117 | hsa-miR-125b-5p | PLA2G2F | -2.01 | 0.00516 | 4.61 | 0.01694 | mirMAP | -0.4 | 0.00804 | NA | |
118 | hsa-miR-324-3p | PLA2G2F | 1.51 | 0.00384 | 4.61 | 0.01694 | mirMAP | -0.66 | 0.00177 | NA | |
119 | hsa-miR-335-5p | PLA2G2F | 0.17 | 0.8039 | 4.61 | 0.01694 | mirMAP | -0.47 | 0.00403 | NA | |
120 | hsa-let-7e-5p | PLA2G3 | -0.11 | 0.81474 | 5.31 | 0.0047 | MirTarget | -0.84 | 0.00023 | NA | |
121 | hsa-miR-125a-3p | PLA2G3 | -0.07 | 0.92074 | 5.31 | 0.0047 | miRanda; miRNATAP | -0.51 | 0.00031 | NA | |
122 | hsa-miR-32-3p | PLA2G3 | 2.2 | 0.03928 | 5.31 | 0.0047 | miRNATAP | -0.6 | 0.00065 | NA | |
123 | hsa-miR-590-3p | PLA2G4A | 2.35 | 0 | -1.19 | 0.31842 | miRanda | -0.36 | 0.00732 | NA | |
124 | hsa-miR-2355-3p | PLA2G6 | 0.49 | 0.48372 | 0.04 | 0.94425 | MirTarget | -0.22 | 0 | NA | |
125 | hsa-miR-125a-5p | PLCG2 | -1.32 | 0.00714 | -1.09 | 0.05438 | miRanda | -0.18 | 0.00558 | NA | |
126 | hsa-miR-335-5p | PLCG2 | 0.17 | 0.8039 | -1.09 | 0.05438 | miRNAWalker2 validate | -0.2 | 3.0E-5 | NA | |
127 | hsa-let-7g-5p | PPP3CA | 0.86 | 0.00648 | -0.1 | 0.76753 | miRNATAP | -0.16 | 0.0088 | NA | |
128 | hsa-miR-142-5p | PRKCA | 3.96 | 0 | -2.51 | 0.0003 | mirMAP | -0.16 | 0.0045 | NA | |
129 | hsa-miR-183-5p | PRKCA | 6.62 | 0 | -2.51 | 0.0003 | miRNATAP | -0.2 | 3.0E-5 | NA | |
130 | hsa-miR-200c-3p | PRKCA | 6.47 | 0 | -2.51 | 0.0003 | miRNATAP | -0.23 | 0.00013 | NA | |
131 | hsa-miR-30e-3p | PRKCA | -0.04 | 0.93258 | -2.51 | 0.0003 | mirMAP | -0.33 | 0.00043 | NA | |
132 | hsa-miR-330-3p | PRKCA | 2.49 | 0.00013 | -2.51 | 0.0003 | mirMAP | -0.17 | 0.00423 | NA | |
133 | hsa-miR-340-5p | PRKCA | 1.41 | 0.00959 | -2.51 | 0.0003 | mirMAP | -0.25 | 0.00068 | NA | |
134 | hsa-miR-374a-3p | PRKCA | 0.47 | 0.30527 | -2.51 | 0.0003 | mirMAP | -0.32 | 0.00024 | NA | |
135 | hsa-miR-374a-5p | PRKCA | 0.28 | 0.45888 | -2.51 | 0.0003 | mirMAP | -0.32 | 0.00335 | NA | |
136 | hsa-miR-590-3p | PRKCA | 2.35 | 0 | -2.51 | 0.0003 | PITA; miRanda; mirMAP; miRNATAP | -0.34 | 1.0E-5 | NA | |
137 | hsa-miR-9-5p | PRKCA | 1.8 | 0.14527 | -2.51 | 0.0003 | miRNATAP | -0.1 | 0.00143 | NA | |
138 | hsa-miR-944 | PRKCA | 7.21 | 0.00082 | -2.51 | 0.0003 | PITA; miRNATAP | -0.16 | 0 | NA | |
139 | hsa-miR-129-5p | PRKCB | -2.67 | 0.00696 | -1.38 | 0.12578 | miRanda; mirMAP | -0.15 | 0.00436 | NA | |
140 | hsa-miR-130a-5p | PRKCB | 1.58 | 0.02435 | -1.38 | 0.12578 | mirMAP | -0.21 | 0.0041 | NA | |
141 | hsa-miR-141-5p | PRKCB | 7.14 | 0 | -1.38 | 0.12578 | mirMAP | -0.19 | 0.00558 | NA | |
142 | hsa-miR-200b-3p | PRKCB | 5.56 | 0 | -1.38 | 0.12578 | MirTarget | -0.3 | 2.0E-5 | NA | |
143 | hsa-miR-200c-3p | PRKCB | 6.47 | 0 | -1.38 | 0.12578 | MirTarget; miRNATAP | -0.35 | 0 | NA | |
144 | hsa-miR-24-3p | PRKCB | 1.56 | 0.00052 | -1.38 | 0.12578 | miRNATAP | -0.35 | 0.00216 | NA | |
145 | hsa-miR-30d-3p | PRKCB | -0.07 | 0.85742 | -1.38 | 0.12578 | mirMAP | -0.47 | 0.00019 | NA | |
146 | hsa-miR-335-3p | PRKCB | 1.2 | 0.09389 | -1.38 | 0.12578 | mirMAP | -0.32 | 1.0E-5 | NA | |
147 | hsa-miR-335-5p | PRKCB | 0.17 | 0.8039 | -1.38 | 0.12578 | mirMAP | -0.26 | 0.00047 | NA | |
148 | hsa-miR-429 | PRKCB | 6.4 | 0 | -1.38 | 0.12578 | MirTarget; miRanda; miRNATAP | -0.36 | 0 | NA | |
149 | hsa-miR-589-3p | PRKCB | 1.33 | 0.05263 | -1.38 | 0.12578 | mirMAP | -0.26 | 0.00057 | NA | |
150 | hsa-miR-590-5p | PRKCB | 1.51 | 0.00239 | -1.38 | 0.12578 | miRanda | -0.3 | 0.00345 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 30 | 1929 | 6.224e-24 | 2.896e-20 |
2 | IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 16 | 323 | 2.384e-19 | 5.547e-16 |
3 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 11 | 74 | 9.091e-19 | 1.058e-15 |
4 | FC RECEPTOR SIGNALING PATHWAY | 14 | 206 | 7.534e-19 | 1.058e-15 |
5 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 26 | 1977 | 5.282e-18 | 4.915e-15 |
6 | INTRACELLULAR SIGNAL TRANSDUCTION | 24 | 1572 | 8.613e-18 | 6.679e-15 |
7 | PLATELET ACTIVATION | 12 | 142 | 2.364e-17 | 1.571e-14 |
8 | GLYCEROLIPID BIOSYNTHETIC PROCESS | 13 | 211 | 5.935e-17 | 3.452e-14 |
9 | GLYCEROPHOSPHOLIPID METABOLIC PROCESS | 14 | 297 | 1.312e-16 | 6.781e-14 |
10 | PHOSPHOLIPID BIOSYNTHETIC PROCESS | 13 | 235 | 2.435e-16 | 1.133e-13 |
11 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 23 | 1656 | 5.153e-16 | 2.18e-13 |
12 | ACTIVATION OF IMMUNE RESPONSE | 15 | 427 | 6.759e-16 | 2.621e-13 |
13 | PHOSPHATIDYLINOSITOL METABOLIC PROCESS | 12 | 193 | 1.005e-15 | 3.596e-13 |
14 | GLYCEROLIPID METABOLIC PROCESS | 14 | 356 | 1.633e-15 | 5.066e-13 |
15 | FC EPSILON RECEPTOR SIGNALING PATHWAY | 11 | 142 | 1.593e-15 | 5.066e-13 |
16 | PHOSPHOLIPID METABOLIC PROCESS | 14 | 364 | 2.222e-15 | 6.462e-13 |
17 | REGULATION OF IMMUNE RESPONSE | 18 | 858 | 3.04e-15 | 8.321e-13 |
18 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 18 | 867 | 3.643e-15 | 9.416e-13 |
19 | REGULATION OF IMMUNE SYSTEM PROCESS | 21 | 1403 | 4.582e-15 | 1.066e-12 |
20 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 18 | 876 | 4.356e-15 | 1.066e-12 |
21 | TRANSMEMBRANE RECEPTOR PROTEIN TYROSINE KINASE SIGNALING PATHWAY | 15 | 498 | 6.509e-15 | 1.442e-12 |
22 | POSITIVE REGULATION OF CELL COMMUNICATION | 21 | 1532 | 2.63e-14 | 5.563e-12 |
23 | POSITIVE REGULATION OF IMMUNE RESPONSE | 15 | 563 | 3.911e-14 | 7.913e-12 |
24 | CELL ACTIVATION | 15 | 568 | 4.449e-14 | 8.625e-12 |
25 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 18 | 1036 | 7.826e-14 | 1.349e-11 |
26 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 18 | 1036 | 7.826e-14 | 1.349e-11 |
27 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 21 | 1618 | 7.738e-14 | 1.349e-11 |
28 | FC GAMMA RECEPTOR SIGNALING PATHWAY | 9 | 95 | 1.215e-13 | 2.019e-11 |
29 | REGULATION OF BODY FLUID LEVELS | 14 | 506 | 2.042e-13 | 3.277e-11 |
30 | LOCOMOTION | 18 | 1114 | 2.703e-13 | 4.192e-11 |
31 | HEMOSTASIS | 12 | 311 | 3.051e-13 | 4.58e-11 |
32 | LIPID BIOSYNTHETIC PROCESS | 14 | 539 | 4.817e-13 | 7.004e-11 |
33 | ENZYME LINKED RECEPTOR PROTEIN SIGNALING PATHWAY | 15 | 689 | 7.284e-13 | 1.027e-10 |
34 | ORGANOPHOSPHATE BIOSYNTHETIC PROCESS | 13 | 450 | 1.035e-12 | 1.417e-10 |
35 | VASCULATURE DEVELOPMENT | 13 | 469 | 1.746e-12 | 2.321e-10 |
36 | ERBB SIGNALING PATHWAY | 8 | 79 | 1.83e-12 | 2.365e-10 |
37 | CELLULAR LIPID METABOLIC PROCESS | 16 | 913 | 2.701e-12 | 3.396e-10 |
38 | PHOSPHATIDYLETHANOLAMINE ACYL CHAIN REMODELING | 6 | 23 | 3.065e-12 | 3.753e-10 |
39 | REGULATION OF KINASE ACTIVITY | 15 | 776 | 4.004e-12 | 4.777e-10 |
40 | IMMUNE SYSTEM PROCESS | 21 | 1984 | 4.152e-12 | 4.83e-10 |
41 | ANGIOGENESIS | 11 | 293 | 4.685e-12 | 5.317e-10 |
42 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 17 | 1135 | 5.404e-12 | 5.987e-10 |
43 | PHOSPHATIDYLCHOLINE ACYL CHAIN REMODELING | 6 | 26 | 6.962e-12 | 7.533e-10 |
44 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 20 | 1805 | 7.928e-12 | 8.384e-10 |
45 | EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 7 | 55 | 9.457e-12 | 9.779e-10 |
46 | CELL MOTILITY | 15 | 835 | 1.136e-11 | 1.125e-09 |
47 | LOCALIZATION OF CELL | 15 | 835 | 1.136e-11 | 1.125e-09 |
48 | PHOSPHORYLATION | 17 | 1228 | 1.888e-11 | 1.83e-09 |
49 | PHOSPHATIDYLGLYCEROL METABOLIC PROCESS | 6 | 31 | 2.211e-11 | 2.1e-09 |
50 | REGULATION OF RESPONSE TO STRESS | 18 | 1468 | 2.811e-11 | 2.616e-09 |
51 | TAXIS | 12 | 464 | 3.308e-11 | 3.018e-09 |
52 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 17 | 1275 | 3.416e-11 | 3.057e-09 |
53 | POSITIVE REGULATION OF MAPK CASCADE | 12 | 470 | 3.839e-11 | 3.248e-09 |
54 | WOUND HEALING | 12 | 470 | 3.839e-11 | 3.248e-09 |
55 | LEUKOCYTE MIGRATION | 10 | 259 | 3.833e-11 | 3.248e-09 |
56 | BLOOD VESSEL MORPHOGENESIS | 11 | 364 | 4.841e-11 | 4.022e-09 |
57 | POSITIVE REGULATION OF KINASE ACTIVITY | 12 | 482 | 5.137e-11 | 4.194e-09 |
58 | PHOSPHATIDYLINOSITOL BIOSYNTHETIC PROCESS | 8 | 120 | 5.58e-11 | 4.457e-09 |
59 | IMMUNE EFFECTOR PROCESS | 12 | 486 | 5.652e-11 | 4.457e-09 |
60 | PROTEIN PHOSPHORYLATION | 15 | 944 | 6.427e-11 | 4.984e-09 |
61 | REGULATION OF TRANSFERASE ACTIVITY | 15 | 946 | 6.621e-11 | 5.027e-09 |
62 | PHAGOCYTOSIS | 9 | 190 | 6.698e-11 | 5.027e-09 |
63 | REGULATION OF TRANSPORT | 19 | 1804 | 8.496e-11 | 6.275e-09 |
64 | REGULATION OF LIPID METABOLIC PROCESS | 10 | 282 | 8.84e-11 | 6.427e-09 |
65 | LIPID METABOLIC PROCESS | 16 | 1158 | 9.552e-11 | 6.837e-09 |
66 | RESPONSE TO EXTERNAL STIMULUS | 19 | 1821 | 9.994e-11 | 7.046e-09 |
67 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 6 | 40 | 1.139e-10 | 7.843e-09 |
68 | PHOSPHATIDYLGLYCEROL ACYL CHAIN REMODELING | 5 | 17 | 1.146e-10 | 7.843e-09 |
69 | POSITIVE REGULATION OF MAP KINASE ACTIVITY | 9 | 207 | 1.439e-10 | 9.707e-09 |
70 | POSITIVE REGULATION OF LOCOMOTION | 11 | 420 | 2.223e-10 | 1.477e-08 |
71 | RESPONSE TO WOUNDING | 12 | 563 | 3.061e-10 | 2.006e-08 |
72 | REGULATION OF CELL MATRIX ADHESION | 7 | 90 | 3.32e-10 | 2.146e-08 |
73 | REGULATION OF PROTEIN MODIFICATION PROCESS | 18 | 1710 | 3.475e-10 | 2.215e-08 |
74 | ORGANOPHOSPHATE METABOLIC PROCESS | 14 | 885 | 3.575e-10 | 2.234e-08 |
75 | REGULATION OF LIPID KINASE ACTIVITY | 6 | 48 | 3.6e-10 | 2.234e-08 |
76 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 17 | 1492 | 3.992e-10 | 2.444e-08 |
77 | PHOSPHATIDYLINOSITOL 3 PHOSPHATE BIOSYNTHETIC PROCESS | 6 | 49 | 4.097e-10 | 2.476e-08 |
78 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 18 | 1791 | 7.385e-10 | 4.405e-08 |
79 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 12 | 616 | 8.528e-10 | 5.023e-08 |
80 | PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 5 | 25 | 9.734e-10 | 5.661e-08 |
81 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 14 | 957 | 9.902e-10 | 5.688e-08 |
82 | REGULATION OF CELL SUBSTRATE ADHESION | 8 | 173 | 1.044e-09 | 5.927e-08 |
83 | REGULATION OF CELL ADHESION | 12 | 629 | 1.081e-09 | 5.949e-08 |
84 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 13 | 788 | 1.087e-09 | 5.949e-08 |
85 | CIRCULATORY SYSTEM DEVELOPMENT | 13 | 788 | 1.087e-09 | 5.949e-08 |
86 | REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 6 | 61 | 1.6e-09 | 8.658e-08 |
87 | ENDOCYTOSIS | 11 | 509 | 1.684e-09 | 9.008e-08 |
88 | REGULATION OF MAPK CASCADE | 12 | 660 | 1.862e-09 | 9.847e-08 |
89 | PHOSPHATIDYLCHOLINE METABOLIC PROCESS | 6 | 64 | 2.152e-09 | 1.125e-07 |
90 | ANTIGEN RECEPTOR MEDIATED SIGNALING PATHWAY | 8 | 195 | 2.692e-09 | 1.392e-07 |
91 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 9 | 289 | 2.739e-09 | 1.401e-07 |
92 | REGULATION OF CELL DEATH | 16 | 1472 | 3.215e-09 | 1.626e-07 |
93 | POSITIVE REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 9 | 296 | 3.376e-09 | 1.689e-07 |
94 | REGULATION OF MAP KINASE ACTIVITY | 9 | 319 | 6.481e-09 | 3.208e-07 |
95 | REGULATION OF PHOSPHATIDYLINOSITOL 3 KINASE SIGNALING | 7 | 138 | 6.745e-09 | 3.303e-07 |
96 | HOMEOSTATIC PROCESS | 15 | 1337 | 7.875e-09 | 3.817e-07 |
97 | ERBB2 SIGNALING PATHWAY | 5 | 39 | 1.035e-08 | 4.938e-07 |
98 | REGULATION OF VESICLE MEDIATED TRANSPORT | 10 | 462 | 1.04e-08 | 4.938e-07 |
99 | ETHANOLAMINE CONTAINING COMPOUND METABOLIC PROCESS | 6 | 85 | 1.22e-08 | 5.677e-07 |
100 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 15 | 1381 | 1.22e-08 | 5.677e-07 |
101 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 15 | 1395 | 1.398e-08 | 6.44e-07 |
102 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 12 | 799 | 1.582e-08 | 7.215e-07 |
103 | PHOSPHATIDYLINOSITOL ACYL CHAIN REMODELING | 4 | 16 | 1.983e-08 | 8.959e-07 |
104 | POSITIVE REGULATION OF DEFENSE RESPONSE | 9 | 364 | 2.031e-08 | 9.088e-07 |
105 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 13 | 1021 | 2.435e-08 | 1.079e-06 |
106 | PHOSPHATIDYLSERINE ACYL CHAIN REMODELING | 4 | 17 | 2.59e-08 | 1.137e-06 |
107 | VESICLE MEDIATED TRANSPORT | 14 | 1239 | 2.702e-08 | 1.175e-06 |
108 | LIPID PHOSPHORYLATION | 6 | 99 | 3.065e-08 | 1.321e-06 |
109 | REGULATION OF CELL PROLIFERATION | 15 | 1496 | 3.57e-08 | 1.524e-06 |
110 | REGULATION OF ADHERENS JUNCTION ORGANIZATION | 5 | 50 | 3.75e-08 | 1.586e-06 |
111 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 15 | 1518 | 4.337e-08 | 1.818e-06 |
112 | CELLULAR RESPONSE TO GROWTH HORMONE STIMULUS | 4 | 20 | 5.251e-08 | 2.181e-06 |
113 | B CELL RECEPTOR SIGNALING PATHWAY | 5 | 54 | 5.567e-08 | 2.292e-06 |
114 | SINGLE ORGANISM BIOSYNTHETIC PROCESS | 14 | 1340 | 7.222e-08 | 2.948e-06 |
115 | ENDOTHELIAL CELL MIGRATION | 5 | 57 | 7.341e-08 | 2.97e-06 |
116 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 16 | 1848 | 8.184e-08 | 3.283e-06 |
117 | INOSITOL LIPID MEDIATED SIGNALING | 6 | 124 | 1.18e-07 | 4.694e-06 |
118 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 11 | 771 | 1.208e-07 | 4.762e-06 |
119 | POSITIVE REGULATION OF LIPID METABOLIC PROCESS | 6 | 128 | 1.426e-07 | 5.574e-06 |
120 | AMINE METABOLIC PROCESS | 6 | 131 | 1.636e-07 | 6.343e-06 |
121 | POSITIVE REGULATION OF VASCULATURE DEVELOPMENT | 6 | 133 | 1.79e-07 | 6.815e-06 |
122 | REGULATION OF CELL JUNCTION ASSEMBLY | 5 | 68 | 1.8e-07 | 6.815e-06 |
123 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 9 | 470 | 1.802e-07 | 6.815e-06 |
124 | POSITIVE REGULATION OF CELL PROLIFERATION | 11 | 814 | 2.085e-07 | 7.823e-06 |
125 | PHOSPHATIDYLSERINE METABOLIC PROCESS | 4 | 28 | 2.195e-07 | 8.17e-06 |
126 | REGULATION OF CELL ACTIVATION | 9 | 484 | 2.308e-07 | 8.524e-06 |
127 | POSITIVE REGULATION OF GENE EXPRESSION | 15 | 1733 | 2.487e-07 | 9.113e-06 |
128 | REGULATION OF CELL DIFFERENTIATION | 14 | 1492 | 2.732e-07 | 9.93e-06 |
129 | RESPONSE TO GROWTH HORMONE | 4 | 30 | 2.93e-07 | 1.057e-05 |
130 | T CELL RECEPTOR SIGNALING PATHWAY | 6 | 146 | 3.108e-07 | 1.113e-05 |
131 | CELLULAR RESPONSE TO NITROGEN COMPOUND | 9 | 505 | 3.3e-07 | 1.172e-05 |
132 | PEPTIDYL SERINE MODIFICATION | 6 | 148 | 3.368e-07 | 1.187e-05 |
133 | RESPONSE TO NITROGEN COMPOUND | 11 | 859 | 3.57e-07 | 1.249e-05 |
134 | REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS | 5 | 78 | 3.596e-07 | 1.249e-05 |
135 | LIPID CATABOLIC PROCESS | 7 | 247 | 3.665e-07 | 1.263e-05 |
136 | NEGATIVE REGULATION OF CELL DEATH | 11 | 872 | 4.146e-07 | 1.419e-05 |
137 | PHOSPHATIDIC ACID METABOLIC PROCESS | 4 | 33 | 4.357e-07 | 1.48e-05 |
138 | REGULATION OF CELL CELL ADHESION | 8 | 380 | 4.688e-07 | 1.581e-05 |
139 | RESPONSE TO BACTERIUM | 9 | 528 | 4.795e-07 | 1.605e-05 |
140 | TISSUE MIGRATION | 5 | 84 | 5.215e-07 | 1.733e-05 |
141 | SECOND MESSENGER MEDIATED SIGNALING | 6 | 160 | 5.331e-07 | 1.759e-05 |
142 | ALDITOL PHOSPHATE METABOLIC PROCESS | 4 | 35 | 5.56e-07 | 1.822e-05 |
143 | REGULATION OF EPITHELIAL CELL MIGRATION | 6 | 166 | 6.616e-07 | 2.153e-05 |
144 | MULTICELLULAR ORGANISMAL HOMEOSTASIS | 7 | 272 | 7.011e-07 | 2.265e-05 |
145 | AMMONIUM ION METABOLIC PROCESS | 6 | 169 | 7.349e-07 | 2.331e-05 |
146 | CALCIUM MEDIATED SIGNALING | 5 | 90 | 7.363e-07 | 2.331e-05 |
147 | CELLULAR RESPONSE TO PEPTIDE | 7 | 274 | 7.364e-07 | 2.331e-05 |
148 | REGULATION OF RESPONSE TO EXTERNAL STIMULUS | 11 | 926 | 7.521e-07 | 2.365e-05 |
149 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 12 | 1142 | 7.684e-07 | 2.4e-05 |
150 | TISSUE HOMEOSTASIS | 6 | 171 | 7.873e-07 | 2.442e-05 |
151 | REPRODUCTIVE SYSTEM DEVELOPMENT | 8 | 408 | 8.014e-07 | 2.469e-05 |
152 | POSITIVE REGULATION OF TRANSPORT | 11 | 936 | 8.362e-07 | 2.543e-05 |
153 | ACTIVATION OF PROTEIN KINASE ACTIVITY | 7 | 279 | 8.313e-07 | 2.543e-05 |
154 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 12 | 1152 | 8.429e-07 | 2.547e-05 |
155 | REGULATION OF DEFENSE RESPONSE | 10 | 759 | 1.052e-06 | 3.158e-05 |
156 | DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION | 9 | 602 | 1.427e-06 | 4.256e-05 |
157 | POSITIVE REGULATION OF EPITHELIAL CELL MIGRATION | 5 | 103 | 1.441e-06 | 4.269e-05 |
158 | REGULATION OF HOMOTYPIC CELL CELL ADHESION | 7 | 307 | 1.574e-06 | 4.634e-05 |
159 | RESPONSE TO ABIOTIC STIMULUS | 11 | 1024 | 2.017e-06 | 5.902e-05 |
160 | RESPONSE TO MOLECULE OF BACTERIAL ORIGIN | 7 | 321 | 2.116e-06 | 6.153e-05 |
161 | NEURON PROJECTION GUIDANCE | 6 | 205 | 2.264e-06 | 6.542e-05 |
162 | REGULATION OF ENDOTHELIAL CELL MIGRATION | 5 | 114 | 2.379e-06 | 6.834e-05 |
163 | LIPID MODIFICATION | 6 | 210 | 2.602e-06 | 7.429e-05 |
164 | REGULATION OF CYTOPLASMIC TRANSPORT | 8 | 481 | 2.738e-06 | 7.769e-05 |
165 | CYTOKINE PRODUCTION | 5 | 120 | 3.064e-06 | 8.639e-05 |
166 | CELLULAR RESPONSE TO STRESS | 13 | 1565 | 3.313e-06 | 9.287e-05 |
167 | REGULATION OF EARLY ENDOSOME TO LATE ENDOSOME TRANSPORT | 3 | 16 | 3.484e-06 | 9.706e-05 |
168 | ALCOHOL METABOLIC PROCESS | 7 | 348 | 3.607e-06 | 9.991e-05 |
169 | CELLULAR HOMEOSTASIS | 9 | 676 | 3.695e-06 | 0.0001017 |
170 | CHEMICAL HOMEOSTASIS | 10 | 874 | 3.738e-06 | 0.0001023 |
171 | NEGATIVE REGULATION OF ANOIKIS | 3 | 17 | 4.225e-06 | 0.000115 |
172 | RESPONSE TO HORMONE | 10 | 893 | 4.526e-06 | 0.0001224 |
173 | REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 4 | 59 | 4.677e-06 | 0.0001258 |
174 | REGULATION OF VASCULATURE DEVELOPMENT | 6 | 233 | 4.738e-06 | 0.0001267 |
175 | OVULATION | 3 | 18 | 5.063e-06 | 0.0001331 |
176 | MAST CELL MEDIATED IMMUNITY | 3 | 18 | 5.063e-06 | 0.0001331 |
177 | INOSITOL PHOSPHATE MEDIATED SIGNALING | 3 | 18 | 5.063e-06 | 0.0001331 |
178 | POSITIVE REGULATION OF CELL ADHESION | 7 | 376 | 5.995e-06 | 0.0001567 |
179 | PLACENTA DEVELOPMENT | 5 | 138 | 6.078e-06 | 0.000158 |
180 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 13 | 1672 | 6.876e-06 | 0.0001777 |
181 | REGULATION OF CELL MORPHOGENESIS | 8 | 552 | 7.54e-06 | 0.0001938 |
182 | POSITIVE REGULATION OF ENDOTHELIAL CELL MIGRATION | 4 | 67 | 7.792e-06 | 0.0001981 |
183 | REGULATION OF ORGANELLE ORGANIZATION | 11 | 1178 | 7.777e-06 | 0.0001981 |
184 | MAST CELL ACTIVATION | 3 | 21 | 8.22e-06 | 0.0002045 |
185 | REGULATION OF CELL PROJECTION ORGANIZATION | 8 | 558 | 8.159e-06 | 0.0002045 |
186 | POSITIVE REGULATION OF ADHERENS JUNCTION ORGANIZATION | 3 | 21 | 8.22e-06 | 0.0002045 |
187 | BONE RESORPTION | 3 | 21 | 8.22e-06 | 0.0002045 |
188 | SINGLE ORGANISM CATABOLIC PROCESS | 10 | 957 | 8.341e-06 | 0.0002064 |
189 | RESPONSE TO ENDOGENOUS STIMULUS | 12 | 1450 | 9.256e-06 | 0.0002279 |
190 | RESPONSE TO PEPTIDE | 7 | 404 | 9.576e-06 | 0.0002321 |
191 | CELLULAR CHEMICAL HOMEOSTASIS | 8 | 570 | 9.527e-06 | 0.0002321 |
192 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 7 | 404 | 9.576e-06 | 0.0002321 |
193 | POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 8 | 573 | 9.898e-06 | 0.0002386 |
194 | REGULATION OF CELLULAR COMPONENT BIOGENESIS | 9 | 767 | 1.026e-05 | 0.0002461 |
195 | AMEBOIDAL TYPE CELL MIGRATION | 5 | 154 | 1.037e-05 | 0.0002474 |
196 | LYSOSOME LOCALIZATION | 3 | 23 | 1.092e-05 | 0.0002578 |
197 | POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS | 3 | 23 | 1.092e-05 | 0.0002578 |
198 | IMMUNE SYSTEM DEVELOPMENT | 8 | 582 | 1.109e-05 | 0.0002592 |
199 | REGULATION OF RESPONSE TO WOUNDING | 7 | 413 | 1.105e-05 | 0.0002592 |
200 | LEUKOCYTE ACTIVATION | 7 | 414 | 1.122e-05 | 0.0002611 |
201 | DEFENSE RESPONSE | 11 | 1231 | 1.181e-05 | 0.0002733 |
202 | POSITIVE REGULATION OF CELL JUNCTION ASSEMBLY | 3 | 24 | 1.246e-05 | 0.0002842 |
203 | REGULATION OF ANOIKIS | 3 | 24 | 1.246e-05 | 0.0002842 |
204 | POSITIVE REGULATION OF LAMELLIPODIUM ORGANIZATION | 3 | 24 | 1.246e-05 | 0.0002842 |
205 | VASCULAR PROCESS IN CIRCULATORY SYSTEM | 5 | 163 | 1.366e-05 | 0.0003099 |
206 | POSITIVE REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 3 | 25 | 1.414e-05 | 0.0003194 |
207 | LYMPHOCYTE COSTIMULATION | 4 | 78 | 1.429e-05 | 0.0003211 |
208 | TISSUE DEVELOPMENT | 12 | 1518 | 1.474e-05 | 0.0003298 |
209 | ANATOMICAL STRUCTURE HOMEOSTASIS | 6 | 285 | 1.495e-05 | 0.0003328 |
210 | POSITIVE REGULATION OF PROTEIN KINASE B SIGNALING | 4 | 81 | 1.659e-05 | 0.0003677 |
211 | REGULATION OF CELLULAR LOCALIZATION | 11 | 1277 | 1.668e-05 | 0.0003678 |
212 | POSITIVE REGULATION OF ERK1 AND ERK2 CASCADE | 5 | 172 | 1.77e-05 | 0.0003871 |
213 | REGULATION OF INTRACELLULAR TRANSPORT | 8 | 621 | 1.772e-05 | 0.0003871 |
214 | RESPONSE TO LITHIUM ION | 3 | 27 | 1.794e-05 | 0.00039 |
215 | REGULATION OF HOMEOSTATIC PROCESS | 7 | 447 | 1.842e-05 | 0.0003986 |
216 | POSITIVE REGULATION OF ACUTE INFLAMMATORY RESPONSE | 3 | 28 | 2.006e-05 | 0.0004321 |
217 | INFLAMMATORY RESPONSE | 7 | 454 | 2.036e-05 | 0.0004345 |
218 | MODULATION OF SYNAPTIC TRANSMISSION | 6 | 301 | 2.035e-05 | 0.0004345 |
219 | PEPTIDYL AMINO ACID MODIFICATION | 9 | 841 | 2.138e-05 | 0.0004542 |
220 | SINGLE ORGANISM CELL ADHESION | 7 | 459 | 2.184e-05 | 0.0004619 |
221 | TISSUE REMODELING | 4 | 87 | 2.202e-05 | 0.0004636 |
222 | REGULATION OF VACUOLAR TRANSPORT | 3 | 29 | 2.235e-05 | 0.0004684 |
223 | LEUKOCYTE DEGRANULATION | 3 | 30 | 2.48e-05 | 0.0005151 |
224 | CELLULAR RESPONSE TO VASCULAR ENDOTHELIAL GROWTH FACTOR STIMULUS | 3 | 30 | 2.48e-05 | 0.0005151 |
225 | RESPONSE TO GROWTH FACTOR | 7 | 475 | 2.72e-05 | 0.0005624 |
226 | RESPONSE TO INORGANIC SUBSTANCE | 7 | 479 | 2.869e-05 | 0.0005908 |
227 | ORGANIC HYDROXY COMPOUND METABOLIC PROCESS | 7 | 482 | 2.986e-05 | 0.0006121 |
228 | POSITIVE REGULATION OF LIPID KINASE ACTIVITY | 3 | 32 | 3.021e-05 | 0.0006166 |
229 | ICOSANOID METABOLIC PROCESS | 4 | 96 | 3.246e-05 | 0.0006483 |
230 | FEMALE GAMETE GENERATION | 4 | 96 | 3.246e-05 | 0.0006483 |
231 | RESPONSE TO BIOTIC STIMULUS | 9 | 886 | 3.224e-05 | 0.0006483 |
232 | REGULATION OF MUSCLE SYSTEM PROCESS | 5 | 195 | 3.235e-05 | 0.0006483 |
233 | FATTY ACID DERIVATIVE METABOLIC PROCESS | 4 | 96 | 3.246e-05 | 0.0006483 |
234 | RESPIRATORY SYSTEM DEVELOPMENT | 5 | 197 | 3.397e-05 | 0.0006754 |
235 | REGULATION OF ENDOCYTOSIS | 5 | 199 | 3.565e-05 | 0.0007058 |
236 | RESPONSE TO FLUID SHEAR STRESS | 3 | 34 | 3.636e-05 | 0.0007168 |
237 | MYELOID LEUKOCYTE MIGRATION | 4 | 99 | 3.664e-05 | 0.0007193 |
238 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 6 | 337 | 3.835e-05 | 0.0007497 |
239 | BONE REMODELING | 3 | 35 | 3.971e-05 | 0.0007732 |
240 | ACTIVATION OF INNATE IMMUNE RESPONSE | 5 | 204 | 4.013e-05 | 0.000778 |
241 | LYMPHOCYTE ACTIVATION | 6 | 342 | 4.163e-05 | 0.0008037 |
242 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 7 | 513 | 4.439e-05 | 0.0008511 |
243 | POSITIVE REGULATION OF PROTEIN IMPORT | 4 | 104 | 4.445e-05 | 0.0008511 |
244 | REGULATION OF CALCIUM ION TRANSPORT | 5 | 209 | 4.504e-05 | 0.0008553 |
245 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 7 | 514 | 4.494e-05 | 0.0008553 |
246 | CELL DEVELOPMENT | 11 | 1426 | 4.647e-05 | 0.0008789 |
247 | REGULATION OF LAMELLIPODIUM ORGANIZATION | 3 | 37 | 4.702e-05 | 0.0008858 |
248 | INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 4 | 106 | 4.789e-05 | 0.0008986 |
249 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 6 | 360 | 5.536e-05 | 0.001026 |
250 | ASTROCYTE DIFFERENTIATION | 3 | 39 | 5.516e-05 | 0.001026 |
251 | REGULATION OF PROTEIN LOCALIZATION | 9 | 950 | 5.558e-05 | 0.001026 |
252 | PEPTIDYL TYROSINE AUTOPHOSPHORYLATION | 3 | 39 | 5.516e-05 | 0.001026 |
253 | POSITIVE REGULATION OF CELL MATRIX ADHESION | 3 | 40 | 5.956e-05 | 0.001095 |
254 | CIRCULATORY SYSTEM PROCESS | 6 | 366 | 6.067e-05 | 0.001111 |
255 | POSITIVE REGULATION OF INFLAMMATORY RESPONSE | 4 | 113 | 6.149e-05 | 0.001122 |
256 | CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION | 6 | 368 | 6.253e-05 | 0.001137 |
257 | MYELOID CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 3 | 41 | 6.417e-05 | 0.001162 |
258 | POSITIVE REGULATION OF CYTOKINE PRODUCTION | 6 | 370 | 6.443e-05 | 0.001162 |
259 | SMALL MOLECULE METABOLIC PROCESS | 12 | 1767 | 6.674e-05 | 0.001199 |
260 | POSITIVE REGULATION OF PHOSPHOLIPID METABOLIC PROCESS | 3 | 42 | 6.902e-05 | 0.001235 |
261 | LEUKOCYTE CHEMOTAXIS | 4 | 117 | 7.041e-05 | 0.001247 |
262 | CELLULAR RESPONSE TO HORMONE STIMULUS | 7 | 552 | 7.048e-05 | 0.001247 |
263 | TUBE DEVELOPMENT | 7 | 552 | 7.048e-05 | 0.001247 |
264 | REGULATION OF SYNAPSE STRUCTURE OR ACTIVITY | 5 | 232 | 7.389e-05 | 0.001301 |
265 | MYELOID LEUKOCYTE MEDIATED IMMUNITY | 3 | 43 | 7.41e-05 | 0.001301 |
266 | POSITIVE REGULATION OF CHEMOTAXIS | 4 | 120 | 7.77e-05 | 0.001359 |
267 | REGULATION OF CYTOKINE PRODUCTION | 7 | 563 | 7.977e-05 | 0.001388 |
268 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 4 | 121 | 8.025e-05 | 0.001388 |
269 | REGULATION OF PROTEIN KINASE B SIGNALING | 4 | 121 | 8.025e-05 | 0.001388 |
270 | MUSCLE CELL DIFFERENTIATION | 5 | 237 | 8.172e-05 | 0.001408 |
271 | CELL DEATH | 9 | 1001 | 8.324e-05 | 0.001426 |
272 | REGULATION OF ERK1 AND ERK2 CASCADE | 5 | 238 | 8.336e-05 | 0.001426 |
273 | LUNG MORPHOGENESIS | 3 | 45 | 8.498e-05 | 0.001448 |
274 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 9 | 1008 | 8.782e-05 | 0.001491 |
275 | PEPTIDYL THREONINE MODIFICATION | 3 | 46 | 9.079e-05 | 0.001536 |
276 | POSITIVE REGULATION OF INNATE IMMUNE RESPONSE | 5 | 246 | 9.74e-05 | 0.001642 |
277 | MUSCLE CELL DEVELOPMENT | 4 | 128 | 9.982e-05 | 0.001677 |
278 | NEURON PROJECTION MORPHOGENESIS | 6 | 402 | 0.0001017 | 0.001703 |
279 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 4 | 129 | 0.0001029 | 0.001716 |
280 | BIOLOGICAL ADHESION | 9 | 1032 | 0.0001052 | 0.001748 |
281 | POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS | 6 | 406 | 0.0001074 | 0.001779 |
282 | BRANCHING MORPHOGENESIS OF AN EPITHELIAL TUBE | 4 | 131 | 0.0001092 | 0.001802 |
283 | B CELL ACTIVATION | 4 | 132 | 0.0001124 | 0.001844 |
284 | REPRODUCTION | 10 | 1297 | 0.0001126 | 0.001844 |
285 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 5 | 258 | 0.0001218 | 0.001988 |
286 | POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 3 | 51 | 0.0001237 | 0.002006 |
287 | REGULATION OF BLOOD VESSEL ENDOTHELIAL CELL MIGRATION | 3 | 51 | 0.0001237 | 0.002006 |
288 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 8 | 823 | 0.0001295 | 0.00209 |
289 | ACTIVATION OF MAPK ACTIVITY | 4 | 137 | 0.0001298 | 0.00209 |
290 | CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE | 4 | 139 | 0.0001373 | 0.002203 |
291 | REGULATION OF SYNAPTIC PLASTICITY | 4 | 140 | 0.0001411 | 0.002256 |
292 | CELL PART MORPHOGENESIS | 7 | 633 | 0.0001652 | 0.002633 |
293 | CELLULAR RESPONSE TO INSULIN STIMULUS | 4 | 146 | 0.0001659 | 0.002634 |
294 | POSITIVE REGULATION OF TUMOR NECROSIS FACTOR SUPERFAMILY CYTOKINE PRODUCTION | 3 | 57 | 0.0001725 | 0.00273 |
295 | POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 5 | 282 | 0.0001844 | 0.002899 |
296 | MUSCLE SYSTEM PROCESS | 5 | 282 | 0.0001844 | 0.002899 |
297 | POSITIVE REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS | 2 | 11 | 0.0001913 | 0.002966 |
298 | CHEMICAL HOMEOSTASIS WITHIN A TISSUE | 2 | 11 | 0.0001913 | 0.002966 |
299 | REGULATION OF FEVER GENERATION | 2 | 11 | 0.0001913 | 0.002966 |
300 | VASCULOGENESIS | 3 | 59 | 0.0001911 | 0.002966 |
301 | MATERNAL PROCESS INVOLVED IN FEMALE PREGNANCY | 3 | 60 | 0.0002009 | 0.003106 |
302 | LEUKOCYTE DIFFERENTIATION | 5 | 292 | 0.0002168 | 0.003341 |
303 | RESPONSE TO LIPID | 8 | 888 | 0.0002183 | 0.003353 |
304 | REGULATION OF GOLGI ORGANIZATION | 2 | 12 | 0.0002292 | 0.003474 |
305 | EMBRYO DEVELOPMENT | 8 | 894 | 0.0002286 | 0.003474 |
306 | TRACHEA MORPHOGENESIS | 2 | 12 | 0.0002292 | 0.003474 |
307 | POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 2 | 12 | 0.0002292 | 0.003474 |
308 | REGULATION OF MUSCLE ADAPTATION | 3 | 63 | 0.0002323 | 0.003509 |
309 | CELL PROLIFERATION | 7 | 672 | 0.0002385 | 0.003591 |
310 | CELLULAR COMPONENT MORPHOGENESIS | 8 | 900 | 0.0002392 | 0.003591 |
311 | CELL PROJECTION ORGANIZATION | 8 | 902 | 0.0002429 | 0.003633 |
312 | CELL CHEMOTAXIS | 4 | 162 | 0.000247 | 0.003672 |
313 | POSITIVE REGULATION OF RESPONSE TO WOUNDING | 4 | 162 | 0.000247 | 0.003672 |
314 | POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION | 5 | 303 | 0.0002573 | 0.003812 |
315 | CELLULAR RESPONSE TO UV | 3 | 66 | 0.0002666 | 0.003926 |
316 | POSITIVE REGULATION OF LIPID BIOSYNTHETIC PROCESS | 3 | 66 | 0.0002666 | 0.003926 |
317 | LIPOXYGENASE PATHWAY | 2 | 13 | 0.0002706 | 0.003972 |
318 | REGULATION OF PROTEIN TARGETING | 5 | 307 | 0.0002733 | 0.003999 |
319 | MORPHOGENESIS OF A BRANCHING STRUCTURE | 4 | 167 | 0.0002774 | 0.004046 |
320 | RESPONSE TO CARBOHYDRATE | 4 | 168 | 0.0002838 | 0.004126 |
321 | POSITIVE REGULATION OF CELL ACTIVATION | 5 | 311 | 0.0002901 | 0.004205 |
322 | POSITIVE REGULATION OF ENDOTHELIAL CELL PROLIFERATION | 3 | 68 | 0.0002912 | 0.004208 |
323 | REGULATION OF RESPIRATORY BURST | 2 | 14 | 0.0003153 | 0.004459 |
324 | VASCULAR ENDOTHELIAL GROWTH FACTOR SIGNALING PATHWAY | 2 | 14 | 0.0003153 | 0.004459 |
325 | REGULATION OF FIBROBLAST APOPTOTIC PROCESS | 2 | 14 | 0.0003153 | 0.004459 |
326 | T CELL MIGRATION | 2 | 14 | 0.0003153 | 0.004459 |
327 | CARDIOLIPIN METABOLIC PROCESS | 2 | 14 | 0.0003153 | 0.004459 |
328 | REGULATION OF PROTEIN KINASE C SIGNALING | 2 | 14 | 0.0003153 | 0.004459 |
329 | POSITIVE REGULATION OF SPROUTING ANGIOGENESIS | 2 | 14 | 0.0003153 | 0.004459 |
330 | STRIATED MUSCLE CELL DIFFERENTIATION | 4 | 173 | 0.0003173 | 0.004473 |
331 | EPITHELIUM DEVELOPMENT | 8 | 945 | 0.0003328 | 0.004679 |
332 | RESPONSE TO CORTICOSTEROID | 4 | 176 | 0.0003387 | 0.004746 |
333 | SYSTEM PROCESS | 11 | 1785 | 0.0003455 | 0.004828 |
334 | REGULATION OF METAL ION TRANSPORT | 5 | 325 | 0.0003551 | 0.004947 |
335 | REGULATION OF SYSTEM PROCESS | 6 | 507 | 0.000357 | 0.004958 |
336 | CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS | 2 | 15 | 0.0003634 | 0.004973 |
337 | REGULATION OF HEAT GENERATION | 2 | 15 | 0.0003634 | 0.004973 |
338 | NEGATIVE REGULATION OF DENDRITE MORPHOGENESIS | 2 | 15 | 0.0003634 | 0.004973 |
339 | RESPIRATORY BURST | 2 | 15 | 0.0003634 | 0.004973 |
340 | REGULATION OF HYDROGEN PEROXIDE METABOLIC PROCESS | 2 | 15 | 0.0003634 | 0.004973 |
341 | REGULATION OF CHEMOTAXIS | 4 | 180 | 0.0003688 | 0.005032 |
342 | CELLULAR RESPONSE TO CARBOHYDRATE STIMULUS | 3 | 74 | 0.0003737 | 0.00507 |
343 | REGULATION OF ACUTE INFLAMMATORY RESPONSE | 3 | 74 | 0.0003737 | 0.00507 |
344 | GRANULOCYTE MIGRATION | 3 | 75 | 0.0003888 | 0.005244 |
345 | CELLULAR GLUCOSE HOMEOSTASIS | 3 | 75 | 0.0003888 | 0.005244 |
346 | REGULATION OF PROTEIN IMPORT | 4 | 183 | 0.0003926 | 0.00528 |
347 | RESPONSE TO METAL ION | 5 | 333 | 0.0003969 | 0.005323 |
348 | POSITIVE REGULATION OF LAMELLIPODIUM ASSEMBLY | 2 | 16 | 0.0004148 | 0.00553 |
349 | POSITIVE REGULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR SIGNALING PATHWAY | 2 | 16 | 0.0004148 | 0.00553 |
350 | PEPTIDYL TYROSINE MODIFICATION | 4 | 186 | 0.0004175 | 0.005551 |
351 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 8 | 983 | 0.0004336 | 0.005749 |
352 | DIVALENT INORGANIC CATION HOMEOSTASIS | 5 | 343 | 0.0004543 | 0.006006 |
353 | REGULATION OF CHROMATIN BINDING | 2 | 17 | 0.0004695 | 0.006067 |
354 | POSITIVE REGULATION OF FATTY ACID BIOSYNTHETIC PROCESS | 2 | 17 | 0.0004695 | 0.006067 |
355 | REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS | 2 | 17 | 0.0004695 | 0.006067 |
356 | REGULATION OF CALCINEURIN NFAT SIGNALING CASCADE | 2 | 17 | 0.0004695 | 0.006067 |
357 | INSULIN RECEPTOR SIGNALING PATHWAY | 3 | 80 | 0.00047 | 0.006067 |
358 | REGULATION OF ENDOTHELIAL CELL CHEMOTAXIS | 2 | 17 | 0.0004695 | 0.006067 |
359 | REGULATION OF PRI MIRNA TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 2 | 17 | 0.0004695 | 0.006067 |
360 | PROTEIN AUTOPHOSPHORYLATION | 4 | 192 | 0.0004707 | 0.006067 |
361 | RESPONSE TO REACTIVE OXYGEN SPECIES | 4 | 191 | 0.0004615 | 0.006067 |
362 | POSITIVE REGULATION OF LEUKOCYTE CHEMOTAXIS | 3 | 81 | 0.0004874 | 0.006265 |
363 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 8 | 1004 | 0.0004993 | 0.0064 |
364 | SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION | 5 | 352 | 0.0005112 | 0.006517 |
365 | RESPONSE TO OXIDATIVE STRESS | 5 | 352 | 0.0005112 | 0.006517 |
366 | NEURON PROJECTION DEVELOPMENT | 6 | 545 | 0.0005237 | 0.006658 |
367 | REGULATION OF MITOCHONDRIAL DEPOLARIZATION | 2 | 18 | 0.0005276 | 0.006689 |
368 | NUCLEAR TRANSPORT | 5 | 355 | 0.0005313 | 0.006717 |
369 | MULTICELLULAR ORGANISM REPRODUCTION | 7 | 768 | 0.0005341 | 0.006735 |
370 | REGULATION OF INNATE IMMUNE RESPONSE | 5 | 357 | 0.000545 | 0.006854 |
371 | EPHRIN RECEPTOR SIGNALING PATHWAY | 3 | 85 | 0.0005613 | 0.007021 |
372 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 6 | 552 | 0.0005601 | 0.007021 |
373 | REGULATION OF NEURON DIFFERENTIATION | 6 | 554 | 0.0005709 | 0.007121 |
374 | CELLULAR RESPONSE TO FLUID SHEAR STRESS | 2 | 19 | 0.000589 | 0.007308 |
375 | REGULATION OF CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS | 2 | 19 | 0.000589 | 0.007308 |
376 | RESPONSE TO INSULIN | 4 | 205 | 0.0006022 | 0.007437 |
377 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 5 | 365 | 0.0006026 | 0.007437 |
378 | OVULATION CYCLE PROCESS | 3 | 88 | 0.0006212 | 0.007646 |
379 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 5 | 370 | 0.0006408 | 0.007861 |
380 | EPITHELIAL CELL PROLIFERATION | 3 | 89 | 0.000642 | 0.007861 |
381 | EMBRYONIC HEMOPOIESIS | 2 | 20 | 0.0006536 | 0.007961 |
382 | TRACHEA DEVELOPMENT | 2 | 20 | 0.0006536 | 0.007961 |
383 | CELLULAR RESPONSE TO LIGHT STIMULUS | 3 | 91 | 0.000685 | 0.008322 |
384 | DECIDUALIZATION | 2 | 21 | 0.0007216 | 0.008743 |
385 | POSITIVE REGULATION OF HOMEOSTATIC PROCESS | 4 | 216 | 0.0007324 | 0.008806 |
386 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 5 | 381 | 0.0007313 | 0.008806 |
387 | POSITIVE REGULATION OF BLOOD CIRCULATION | 3 | 93 | 0.0007298 | 0.008806 |
388 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 4 | 218 | 0.000758 | 0.00909 |
389 | REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 3 | 95 | 0.0007764 | 0.009263 |
390 | TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 3 | 95 | 0.0007764 | 0.009263 |
391 | NEGATIVE REGULATION OF MUSCLE CONTRACTION | 2 | 22 | 0.0007928 | 0.009291 |
392 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 4 | 220 | 0.0007843 | 0.009291 |
393 | POSITIVE REGULATION OF MUSCLE HYPERTROPHY | 2 | 22 | 0.0007928 | 0.009291 |
394 | POSITIVE REGULATION OF PROTEIN AUTOPHOSPHORYLATION | 2 | 22 | 0.0007928 | 0.009291 |
395 | CELLULAR MODIFIED AMINO ACID METABOLIC PROCESS | 4 | 220 | 0.0007843 | 0.009291 |
396 | POSITIVE REGULATION OF CARDIAC MUSCLE HYPERTROPHY | 2 | 22 | 0.0007928 | 0.009291 |
397 | ERK1 AND ERK2 CASCADE | 2 | 22 | 0.0007928 | 0.009291 |
398 | MYELOID LEUKOCYTE DIFFERENTIATION | 3 | 96 | 0.0008004 | 0.00931 |
399 | REGULATION OF PROTEIN STABILITY | 4 | 221 | 0.0007977 | 0.00931 |
400 | REGULATION OF LEUKOCYTE CHEMOTAXIS | 3 | 96 | 0.0008004 | 0.00931 |
401 | NEGATIVE REGULATION OF CELL ADHESION | 4 | 223 | 0.0008249 | 0.009572 |
402 | REGULATED EXOCYTOSIS | 4 | 224 | 0.0008388 | 0.009708 |
403 | MYELOID LEUKOCYTE ACTIVATION | 3 | 98 | 0.0008498 | 0.009787 |
404 | REGULATION OF ENDOTHELIAL CELL PROLIFERATION | 3 | 98 | 0.0008498 | 0.009787 |
405 | GLAND DEVELOPMENT | 5 | 395 | 0.00086 | 0.00988 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | KINASE ACTIVITY | 16 | 842 | 7.893e-13 | 7.333e-10 |
2 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 16 | 992 | 9.455e-12 | 4.392e-09 |
3 | PHOSPHOLIPASE A2 ACTIVITY | 6 | 31 | 2.211e-11 | 6.847e-09 |
4 | PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 7 | 70 | 5.474e-11 | 1.271e-08 |
5 | X1 PHOSPHATIDYLINOSITOL 3 KINASE ACTIVITY | 6 | 43 | 1.801e-10 | 3.346e-08 |
6 | PHOSPHATIDYLINOSITOL KINASE ACTIVITY | 6 | 51 | 5.262e-10 | 6.984e-08 |
7 | PHOSPHOLIPASE ACTIVITY | 7 | 94 | 4.524e-10 | 6.984e-08 |
8 | RIBONUCLEOTIDE BINDING | 18 | 1860 | 1.363e-09 | 1.582e-07 |
9 | LIPASE ACTIVITY | 7 | 117 | 2.124e-09 | 2.193e-07 |
10 | PROTEIN KINASE ACTIVITY | 11 | 640 | 1.812e-08 | 1.675e-06 |
11 | PHOSPHATIDYLINOSITOL PHOSPHATE KINASE ACTIVITY | 4 | 16 | 1.983e-08 | 1.675e-06 |
12 | CARBOXYLIC ESTER HYDROLASE ACTIVITY | 6 | 135 | 1.956e-07 | 1.514e-05 |
13 | INSULIN RECEPTOR SUBSTRATE BINDING | 3 | 11 | 1.033e-06 | 7.383e-05 |
14 | KINASE BINDING | 9 | 606 | 1.507e-06 | 8.391e-05 |
15 | KINASE REGULATOR ACTIVITY | 6 | 186 | 1.287e-06 | 8.391e-05 |
16 | CALCIUM DEPENDENT PROTEIN KINASE ACTIVITY | 3 | 12 | 1.376e-06 | 8.391e-05 |
17 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 8 | 445 | 1.536e-06 | 8.391e-05 |
18 | ADENYL NUCLEOTIDE BINDING | 13 | 1514 | 2.29e-06 | 0.0001182 |
19 | HYDROLASE ACTIVITY ACTING ON ESTER BONDS | 9 | 739 | 7.609e-06 | 0.000372 |
20 | ENZYME BINDING | 13 | 1737 | 1.043e-05 | 0.0004845 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | PHOSPHATIDYLINOSITOL 3 KINASE COMPLEX | 7 | 20 | 3.789e-15 | 2.213e-12 |
2 | EXTRINSIC COMPONENT OF MEMBRANE | 11 | 252 | 9.105e-13 | 2.659e-10 |
3 | TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 7 | 237 | 2.772e-07 | 5.396e-05 |
4 | CELL SUBSTRATE JUNCTION | 7 | 398 | 8.688e-06 | 0.001015 |
5 | MAST CELL GRANULE | 3 | 21 | 8.22e-06 | 0.001015 |
6 | MEMBRANE MICRODOMAIN | 6 | 288 | 1.586e-05 | 0.001477 |
7 | LAMELLIPODIUM | 5 | 172 | 1.77e-05 | 0.001477 |
8 | PLASMA MEMBRANE RAFT | 4 | 86 | 2.104e-05 | 0.001536 |
9 | ANCHORING JUNCTION | 7 | 489 | 3.274e-05 | 0.002124 |
10 | CYTOSKELETON | 13 | 1967 | 3.958e-05 | 0.002312 |
11 | CELL LEADING EDGE | 6 | 350 | 4.735e-05 | 0.002514 |
12 | EXTRINSIC COMPONENT OF PLASMA MEMBRANE | 4 | 136 | 0.0001262 | 0.006141 |
13 | ACTIN CYTOSKELETON | 6 | 444 | 0.0001749 | 0.007858 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | hsa04370_VEGF_signaling_pathway | 38 | 76 | 1.358e-97 | 2.445e-95 | |
2 | hsa04664_Fc_epsilon_RI_signaling_pathway | 23 | 79 | 2.257e-47 | 2.031e-45 | |
3 | hsa04662_B_cell_receptor_signaling_pathway | 22 | 75 | 2.989e-45 | 1.793e-43 | |
4 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 22 | 136 | 7.069e-39 | 3.181e-37 | |
5 | hsa04014_Ras_signaling_pathway | 23 | 236 | 1.996e-35 | 7.187e-34 | |
6 | hsa04660_T_cell_receptor_signaling_pathway | 18 | 108 | 1.056e-31 | 3.169e-30 | |
7 | hsa04012_ErbB_signaling_pathway | 17 | 87 | 3.629e-31 | 9.331e-30 | |
8 | hsa04666_Fc_gamma_R.mediated_phagocytosis | 17 | 95 | 1.866e-30 | 4.199e-29 | |
9 | hsa04510_Focal_adhesion | 19 | 200 | 1.251e-28 | 2.503e-27 | |
10 | hsa04010_MAPK_signaling_pathway | 20 | 268 | 4.609e-28 | 8.297e-27 | |
11 | hsa04062_Chemokine_signaling_pathway | 17 | 189 | 4.446e-25 | 7.274e-24 | |
12 | hsa04722_Neurotrophin_signaling_pathway | 15 | 127 | 6.415e-24 | 9.623e-23 | |
13 | hsa04670_Leukocyte_transendothelial_migration | 14 | 117 | 2.117e-22 | 2.931e-21 | |
14 | hsa04151_PI3K_AKT_signaling_pathway | 18 | 351 | 3.941e-22 | 5.067e-21 | |
15 | hsa04380_Osteoclast_differentiation | 14 | 128 | 7.907e-22 | 9.489e-21 | |
16 | hsa04960_Aldosterone.regulated_sodium_reabsorption | 11 | 42 | 9.688e-22 | 1.09e-20 | |
17 | hsa04912_GnRH_signaling_pathway | 13 | 101 | 3.044e-21 | 3.152e-20 | |
18 | hsa04730_Long.term_depression | 12 | 70 | 3.152e-21 | 3.152e-20 | |
19 | hsa04810_Regulation_of_actin_cytoskeleton | 15 | 214 | 2.093e-20 | 1.983e-19 | |
20 | hsa04150_mTOR_signaling_pathway | 10 | 52 | 2.518e-18 | 2.266e-17 | |
21 | hsa04914_Progesterone.mediated_oocyte_maturation | 11 | 87 | 5.994e-18 | 5.137e-17 | |
22 | hsa04360_Axon_guidance | 12 | 130 | 7.942e-18 | 6.498e-17 | |
23 | hsa04910_Insulin_signaling_pathway | 12 | 138 | 1.662e-17 | 1.3e-16 | |
24 | hsa04620_Toll.like_receptor_signaling_pathway | 11 | 102 | 3.742e-17 | 2.807e-16 | |
25 | hsa04973_Carbohydrate_digestion_and_absorption | 9 | 44 | 7.838e-17 | 5.644e-16 | |
26 | hsa04070_Phosphatidylinositol_signaling_system | 10 | 78 | 1.937e-16 | 1.341e-15 | |
27 | hsa04210_Apoptosis | 10 | 89 | 7.719e-16 | 5.146e-15 | |
28 | hsa04270_Vascular_smooth_muscle_contraction | 10 | 116 | 1.196e-14 | 7.69e-14 | |
29 | hsa04310_Wnt_signaling_pathway | 10 | 151 | 1.756e-13 | 1.09e-12 | |
30 | hsa04972_Pancreatic_secretion | 9 | 101 | 2.143e-13 | 1.286e-12 | |
31 | hsa04720_Long.term_potentiation | 8 | 70 | 6.703e-13 | 3.892e-12 | |
32 | hsa00592_alpha.Linolenic_acid_metabolism | 6 | 20 | 1.182e-12 | 6.647e-12 | |
33 | hsa00590_Arachidonic_acid_metabolism | 7 | 59 | 1.581e-11 | 8.625e-11 | |
34 | hsa00591_Linoleic_acid_metabolism | 6 | 30 | 1.786e-11 | 9.454e-11 | |
35 | hsa00565_Ether_lipid_metabolism | 6 | 36 | 5.81e-11 | 2.988e-10 | |
36 | hsa04975_Fat_digestion_and_absorption | 6 | 46 | 2.756e-10 | 1.378e-09 | |
37 | hsa04540_Gap_junction | 7 | 90 | 3.32e-10 | 1.615e-09 | |
38 | hsa04630_Jak.STAT_signaling_pathway | 8 | 155 | 4.357e-10 | 2.064e-09 | |
39 | hsa00564_Glycerophospholipid_metabolism | 6 | 80 | 8.437e-09 | 3.894e-08 | |
40 | hsa04916_Melanogenesis | 6 | 101 | 3.457e-08 | 1.556e-07 | |
41 | hsa00562_Inositol_phosphate_metabolism | 5 | 57 | 7.341e-08 | 3.223e-07 | |
42 | hsa04530_Tight_junction | 6 | 133 | 1.79e-07 | 7.671e-07 | |
43 | hsa04020_Calcium_signaling_pathway | 6 | 177 | 9.632e-07 | 4.032e-06 | |
44 | hsa04520_Adherens_junction | 4 | 73 | 1.097e-05 | 4.49e-05 | |
45 | hsa04320_Dorso.ventral_axis_formation | 3 | 25 | 1.414e-05 | 5.656e-05 | |
46 | hsa04114_Oocyte_meiosis | 4 | 114 | 6.364e-05 | 0.000249 | |
47 | hsa04971_Gastric_acid_secretion | 2 | 74 | 0.008711 | 0.03336 | |
48 | hsa04970_Salivary_secretion | 2 | 89 | 0.01241 | 0.04652 | |
49 | hsa04144_Endocytosis | 2 | 203 | 0.05678 | 0.2086 |
Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
---|---|---|---|---|---|---|---|---|---|---|
1 | MAGI2-AS3 |
hsa-miR-130a-5p;hsa-miR-149-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-19b-1-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-429;hsa-miR-590-3p | 10 | KDR | Sponge network | -4.563 | 0 | -3.788 | 0 | 0.657 |
2 | RP11-389C8.2 | hsa-miR-130a-5p;hsa-miR-149-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-19b-1-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-3065-3p;hsa-miR-429 | 10 | KDR | Sponge network | -3.089 | 2.0E-5 | -3.788 | 0 | 0.633 |
3 | DNM3OS | hsa-miR-149-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-19b-1-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-3065-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p | 11 | KDR | Sponge network | -3.933 | 0.00059 | -3.788 | 0 | 0.586 |
4 | MIR143HG | hsa-miR-130a-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-19b-1-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-3065-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p | 11 | KDR | Sponge network | -6.51 | 0 | -3.788 | 0 | 0.565 |
5 | HAND2-AS1 |
hsa-miR-130a-5p;hsa-miR-149-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-19b-1-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-429;hsa-miR-590-3p | 10 | KDR | Sponge network | -7.871 | 0 | -3.788 | 0 | 0.447 |
6 | ADAMTS9-AS1 |
hsa-miR-130a-5p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-19b-1-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-590-5p | 10 | KDR | Sponge network | -8.573 | 0.00012 | -3.788 | 0 | 0.425 |
7 | MAGI2-AS3 |
hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-24-3p;hsa-miR-26b-3p;hsa-miR-30b-5p;hsa-miR-335-3p;hsa-miR-33a-3p;hsa-miR-3607-3p;hsa-miR-590-3p | 12 | NFATC2 | Sponge network | -4.563 | 0 | -0.286 | 0.824 | 0.384 |
8 | MAGI2-AS3 |
hsa-miR-130a-5p;hsa-miR-141-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-24-3p;hsa-miR-30d-3p;hsa-miR-335-3p;hsa-miR-429;hsa-miR-589-3p;hsa-miR-9-3p | 10 | PRKCB | Sponge network | -4.563 | 0 | -1.378 | 0.12578 | 0.313 |
9 | HAND2-AS1 |
hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-2355-5p;hsa-miR-24-3p;hsa-miR-26b-3p;hsa-miR-335-3p;hsa-miR-33a-3p;hsa-miR-3607-3p;hsa-miR-590-3p | 12 | NFATC2 | Sponge network | -7.871 | 0 | -0.286 | 0.824 | 0.297 |